ReviewClinical epidemiology2023
Association Between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review and Meta-Analysis.
Review in Clinical epidemiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- The Correlation Between Serum Uric Acid and Metabolic Dysfunction-Associated Fatty Liver Disease: An Updated Systematic Review and Meta-Analysis.Journal of general internal medicine · 2026Pooled it
- Association of serum uric acid and serum uric acid/creatinine ratio with metabolic dysfunction-associated fatty liver disease in young adults: a retrospective study.BMC endocrine disorders · 2026Article
- Application of Multivariate Adaptive Regression Splines to Estimate Fatty Liver Index in Healthy Young Taiwanese Men.Diagnostics (Basel, Switzerland) · 2026Article
- Uric acid and hyperuricemia in relation to non-alcoholic fatty liver disease among individuals with type 2 diabetes: insights from a cross-sectional analysis.Frontiers in endocrinology · 2026Article
- Life-course BMI trajectories and long-term weight gain in relation to hepatic steatosis in a rural community-based cohort in Southwest China.Frontiers in public health · 2026Article
- Association between uric acid and non-alcoholic fatty liver disease in patients with hypertension.PloS one · 2026Article
- Machine Learning-Based Risk Stratification for Metabolic Dysfunction Severity Among Diabetic Patients With Established MASLD: Distinguishing Normal-Weight From Overweight Individuals.Journal of diabetes research · 2026Article
- Assessment of health-related quality of life of patients with gout and hyperuricemia in the Tianjin area according to the SF-6Dv2 scale.Frontiers in public health · 2026Article
- High serum uric acid as a marker for fatty pancreas disease in Chinese women with overweight/obesity.BMC endocrine disorders · 2025Article
- Proteomic signatures of sweetened beverages are associated with higher risk of adverse liver outcomes.Nature food · 2025Article
- Observational
- Development and validation of a new diagnostic prediction model for NAFLD based on machine learning algorithms in NHANES 2017-2020.3.Hormones (Athens, Greece) · 2025Article
- Hyperuricemia-Especially "Metabolic Hyperuricemia"-Is Independently Associated with a Higher Risk of Steatotic Liver Disease.Metabolites · 2025Article
- Combined effect of fasting blood glucose and serum uric acid on nonalcoholic fatty liver disease.Lipids in health and disease · 2025Article
- The associations between serum carotenoids and hyperuricemia among U.S. National Health and Nutrition Examination Survey.BMC public health · 2025Article
- Serum uric acid to high-density lipoprotein cholesterol ratio predicts all-cause mortality in adults with metabolic dysfunction associated steatotic liver disease.Scientific reports · 2025Article
- Gout drives metabolic dysfunction-associated steatotic liver disease through gut microbiota and inflammatory mediators.Scientific reports · 2025Article
- Clinical Insights into Non-Alcoholic Fatty Liver Disease and the Therapeutic Potential of Flavonoids: An Update.Nutrients · 2025Review
- Serum uric acid as a biomarker for metabolic dysfunction-associated steatotic liver disease: insights from ultrasound elastography in a Chinese cohort.BMC gastroenterology · 2025Article
- Insulin resistance as a mediator in the association between nickel exposure and metabolic dysfunction-associated steatotic liver disease.Diabetology & metabolic syndrome · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Recent epidemiological evidence shows that there is an association between serum uric acid (SUA) levels and nonalcoholic fatty liver disease (NAFLD). The purpose of this meta-analysis is to summarize all available evidence and assess the associations between SUA levels and NAFLD. Methods: Using two databases, Web of Science and PubMed, observational studies were applied from the establishment of the databases to June 2022. We used a random effect model to construct the pooled odds ratio (OR) and 95% confidence interval (CI) to appraise the association between SUA levels and NAFLD. The Begg's test was conducted to appraise publication bias. Results: A total of 50 studies were included, involving 2,079,710 participants (719,013 NAFLD patients). The prevalence and incidence rates (95% CIs) of NAFLD in the patients with hyperuricemia were 65% (57-73%) and 31% (20-41%), respectively. Compared to participants with lower levels of SUA, the pooled OR (95% CI) of NAFLD in those with higher levels of SUA was 1.88 (95% CI: 1.76-2.00). In the subgroup analyses, we found that SUA levels were positively associated with NAFLD in all subgroups, according to study design, study quality, sample size, sex, comparison, age, or country. Conclusion: This meta-analysis shows that increased SUA levels are positively associated with NAFLD. The results suggested that reducing SUA levels can be a potential strategy for the prevention of NAFLD. Registration Number: PROSPERO-CRD42022358431.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.